UNITED STATES
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on this Web site for historical purposes only. CIBA VISION assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
Released 12/03/2004
New CIBA VISION Rebate Program Encourages Patient Upgrades
ATLANTA - To encourage patients to try its silicone hydrogel, daily disposable and color contact lens brands, CIBA VISION today announces the "Fitting Choices Refit Rebate," a new high-value rebate program that will continue through March 2005.
Patients who purchase two boxes of O2OPTIX™, NIGHT & DAY®, Focus® DAILIES® (90 packs) or FreshLook® color lenses will receive a $40 rebate to help offset their fitting and exam fees. To qualify for the rebate, patients must be transferring from another brand of contact lenses, including CIBA VISION brand lenses.
"Patients are sometimes reluctant to try new lenses because they incur the expense of a refitting fee when making a switch," said Dwight H. Akerman, OD, FAAO, director of professional marketing for CIBA VISION North America. "The 'Fitting Choices Refit Rebate' program is designed to defray this expense and encourage refitting into CIBA VISION's market leading lenses."
Rebate tear pads will be offered to accounts who meet certain purchase requirements. Details on the "Fitting Choices Refit Rebate" and rebate pads are available from CIBA VISION sales representatives and CAN-DO distributors.
With worldwide headquarters in Atlanta, CIBA VISION is a global leader in research, development and manufacturing of optical and ophthalmic products and services, including contact lenses and lens care products. CIBA VISION products are available in more than 70 countries. For more information, visit the CIBA VISION web site at www.cibavision.com.
CIBA VISION is the eye care unit of Novartis AG (NYSE: NVS), a world leader in pharmaceuticals and consumer health. In 2003, the Group's businesses achieved sales of USD 24.9 billion and a net income of USD 5.0 billion. The Group invested approximately USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 80,000 people and operate in over 140 countries around the world. For further information please consult www.novartis.com.